Cytosorb Therapy in Cardiac Surgery

Cytosorb Therapy in Cardiac Surgery - a Retrospective Study of Hemoadsorption in Patients With Endocarditis

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04309591

Enrollment

249

Registered

2020-03-16

Start date

2019-10-18

Completion date

2019-12-04

Last updated

2020-03-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiopulmonary Surgery, Endocarditis, Peri-operative Cytokines Levels

Keywords

cytokine clearance, cardiac surgery, CytoSorb, cytokine removal

Brief summary

Cardiopulmonary surgery is associated with inflammatory responses that can lead to systemic inflammatory responses (SIRS), organ dysfunction (MOD) and death especially in patients with endocarditis. Cytokine removal might therefore improve outcomes of patients undergoing cardiac surgery. CytoSorb is a device designed to remove cytokine (IL-6, IL-10, TNFalpha) from the blood to reduce immune reactions. This trial investigates the use of CytoSorb during cardiac surgery in patients with endocarditis at the University Hospital Basel.

Interventions

DEVICECytoSorb haemoadsorption (HA) device

CytoSorb® cartridges contain biocompatible sorbent polystyrene divinylbenzene beads coated with polyvinylpyrrolidone, capable of removing inflammatory molecules (eg Interleukin). The cartridge is inserted in a cardio-pulmonary bypass circuit to remove inflammatory molecules during cardiac surgery .

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* patients with endocarditis undergoing cardiac surgery with cardio-pulmonary bypass circuit

Exclusion criteria

* denial of consent for data use

Design outcomes

Primary

Measure	Time frame	Description
In-Hospital mortality	during hospital stay for cardiac surgery from admission until discharge (approximately 15 days)	In-Hospital mortality (number of deaths) of patients with endocarditis undergoing cardiac surgery and intra-operative CytoSorb haemoadsorption

Secondary

Measure	Time frame	Description
time in intensive care unit (days)	during hospital stay for cardiac surgery from admission until discharge (approximately 15 days)	time in intensive care unit (days)
In-Hospital time (days)	hospital stay for cardiac surgery from admission until discharge (approximately 15 days)	In-Hospital time (days)

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026